INS and type 2 diabetes mellitus: Popular oral drugs used in the treatment of type 2 diabetes (sulfonylureas, thiazolidinediones), as well as human insulin preparations (for both types), cause weight gain, which are consequently unfavorable for the metabolic control profile and increase the risk of cardiovascular diseases, often despite a reduction in glycated hemoglobin (HbA1c) [101].